Skip to main content
Fig. 11 | Stem Cell Research & Therapy

Fig. 11

From: A novel therapeutic approach for inflammatory bowel disease by exosomes derived from human umbilical cord mesenchymal stem cells to repair intestinal barrier via TSG-6

Fig. 11

Injections of exogenous TSG-6 exerted a protective effect against colitis. a Schematic representation of experimental design. Recombinant human TSG-6 was injected intraperitoneally at 4 μg per mouse from day 5 to day 9. b Survival rate of mice in the DSS+ PBS and DSS + TSG-6 groups (n = 5–6 per group). Body weight (c), DAI (d), colonic macroscopic images (e), colon length (f), MPO (g), H&E staining and histological score (h) in the control, DSS + PBS, DSS + TSG-6 groups. i Quantitative analysis of PAS-positive goblet cells. Data are presented as mean ± SD. *P < 0.05, ***P < 0.001 and ns indicates P > 0.05

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512